Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Stock Price, News & Analysis

Company Overview

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Key Stats

• Today's Range: $8.61 to $8.80
• 50-Day Range: $7.40 to $8.79
• 52-Week Range: $6.22 to $8.97
• Volume: 55,935 shs
• Average Volume: 60,826 shs
• Market Capitalization: $14.89 billion
• P/E Ratio: 14.98
• Dividend Yield: 1.71%
• Price Target: N/A
• Consensus Rating: N/A

Shionogi & Co., Ltd. Unsponsored ADR Stock Analysis - MarketRank™

Shionogi & Co., Ltd. Unsponsored ADR scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Shionogi & Co., Ltd. Unsponsored ADR.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -1.52%

Earnings Growth

Earnings for Shionogi & Co., Ltd. Unsponsored ADR are expected to decrease by -1.52% in the coming year, from $0.66 to $0.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Shionogi & Co., Ltd. Unsponsored ADR is 14.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.95.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shionogi & Co., Ltd. Unsponsored ADR is 14.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.90.

Price to Earnings Growth Ratio

Shionogi & Co., Ltd. Unsponsored ADR has a PEG Ratio of 2.02. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Shionogi & Co., Ltd. Unsponsored ADR has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Shionogi & Co., Ltd. Unsponsored ADR has been sold short.

Short Interest Ratio / Days to Cover

Shionogi & Co., Ltd. Unsponsored ADR has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shionogi & Co., Ltd. Unsponsored ADR has recently increased by 34.70%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Shionogi & Co., Ltd. Unsponsored ADR pays a meaningful dividend of 1.74%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Shionogi & Co., Ltd. Unsponsored ADR does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Shionogi & Co., Ltd. Unsponsored ADR will have a dividend payout ratio of 23.08% next year. This indicates that Shionogi & Co., Ltd. Unsponsored ADR will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the float of Shionogi & Co., Ltd. Unsponsored ADR has been sold short.

Short Interest Ratio / Days to Cover

Shionogi & Co., Ltd. Unsponsored ADR has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shionogi & Co., Ltd. Unsponsored ADR has recently increased by 34.70%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: N/A

News Sentiment

Shionogi & Co., Ltd. Unsponsored ADR has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Shionogi & Co., Ltd. Unsponsored ADR this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shionogi & Co., Ltd. Unsponsored ADR insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 1.92% of the stock of Shionogi & Co., Ltd. Unsponsored ADR is held by institutions.

SGIOY Stock Analysis - Frequently Asked Questions

How have SGIOY shares performed this year?

Shionogi & Co., Ltd. Unsponsored ADR's stock was trading at $6.9599 at the beginning of the year. Since then, SGIOY stock has increased by 25.7% and is now trading at $8.75.
View the best growth stocks for 2025 here.

How were Shionogi & Co., Ltd. Unsponsored ADR's earnings last quarter?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) posted its quarterly earnings results on Monday, May, 12th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by $0.03. The firm had revenue of $721.77 million for the quarter, compared to analysts' expectations of $824.23 million.

How do I buy shares of Shionogi & Co., Ltd. Unsponsored ADR?

Shares of SGIOY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/12/2025
• Today: 6/28/2025
• Next Earnings (Estimated): 7/28/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:SGIOY
• CIK: 1281721
• Web: www.shionogi.co.jp
• Phone: (166) 202-2161
• Fax: N/A
• Employees: 4,959
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 14.98
• Forward P/E Ratio: 13.26
• P/E Growth: 2.02
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 6.63
• Quick Ratio: 6.13

Sales & Book Value

• Annual Sales: $2.88 billion
• Price / Sales: 5.17
• Cash Flow: $0.74 per share
• Price / Cash Flow: 11.89
• Book Value: $5.29 per share
• Price / Book: 1.65

Miscellaneous

• Outstanding Shares: 1,701,380,000
• Free Float: N/A
• Market Cap: $14.89 billion
• Optionable: Not Optionable
• Beta: 0.18